Barrett's esophagus, or the presence of specialized intestinal mucosa in the esophagus that has a malignant potential, has experienced a rapid increase in diagnosis and prevalence over the past few decades. Once thought to progress to adenocarcinoma in an orderly sequence of increasing dysplasia, recent data suggest the process can be more random. In combination with targeted surveillance endoscopy, recent improvements in technology have aided endoluminal therapy in becoming a cost-effective adjunct to medication. When used in combination, in particular, these ablative therapies have become suitable, if not preferable, alternatives to surgery in many patients.
Abe, Y., Ohara, S., Koike, T., Sekine, H., Iijima, K., Kawamura, M. et al. (2004) The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett's esophagus in Japan. Am J Gastroenterol99: 1213-1221.
2.
Abrams, J.A., Fedi, P., Vakiani, E., Hatefi, D., Remotti, H.E. and Lightdale, C.J. (2008) Depth of resection using two different endoscopic mucosal resection techniques. Endoscopy40: 395-399.
3.
Ackroyd, R., Brown, N.J., Davis, M.F., Stephenson, T.J., Marcus, S.L., Stoddard, C.J. et al. (2000) Photodynamic therapy for dysplastic Barrett's esophagus: a prospective, double blind, randomised, placebo-controlled trial . Gut47: 613-617.
4.
Ackroyd, R., Brown, N.J., Stephenson, T.J., Stoddard, C.J. and Reed, M.W. (1999) Ablation treatment for Barrett esophagus: what depth of tissue destruction is needed. J Clin Pathol52: 509-512.
5.
Anderson, L.A., Murray, L.J., Murphy, S.J., Fitzpatrick, D.A., Johnston, B.T., Watson, R.G.P. et al. (2003) Mortality in Barrett's esophagus: results from a population based study. Gut52: 1081-1084.
6.
Attwood, S.E.A. and Morris, C.D. (2001) Who defines Barrett's esophagus: endoscopist or pathologist. Eur J Gastroenterol13: 97-99.
7.
Banki, F., DeMeester, S.R., Mason, R.J., Campus, G., Hagen, J.A., Peters, J.H. et al. (2005) Barrett's esophagus in females: a comparative analysis of risk factors in females and males. Am J Gastroenterol100: 560-567.
8.
Barham, C.P., Shepherd, N. and Barr, H. (1996) Regression of Barrett's epithelium using argon gas coagulation and acid suppression. Gut39: 114.
9.
Barr, H. (2000) Barrett's esophagus: treatment with 5-aminolevulinic acid photodynamic therapy. Gastrointest Clin Endoscop N Am10: 421-438.
10.
Barr, H., Stone, N. and Rembacken, B. (2005) Endoscopic therapy for Barrett's esophagus. Gut54: 875-884.
11.
Barrett, N.R. (1950) Chronic peptic ulcer of the esophagus and `esophagitis' . Br J Surg38: 175-182.
12.
Barrett, N.R. (1957) The lower esophagus lined by columnar epithelium . Surgery41: 881-894.
13.
Bergman, J.J. (2005) Diagnosis and therapy of early neoplasia in Barrett's esophagus. Curr Opin Gastroenterol21: 466-471.
14.
Biddlestone, L.R., Barham, C.P., Wilkinson, S.P., Barr, H. and Shepherd, N.A. (1998) The histopathology of treated Barrett's esophagus . Am J Surg Pathol22: 239-245.
15.
Birkmeyer, J.D., Siewers, A.E., Finlayson, E.V., Stukel, T.A., Lucas, F.L., Batista, I. et al. (2002) Hospital volume and surgical mortality in the United States. N Engl J Med346: 1128-1137.
16.
Blot, W.J., Devesa, S.S., Kneller, R.W. and Fraumeni Jr, J.F. (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA265: 1287-1289.
17.
Bollschweiler, E., Wolfgarten, E., Gutschow, C. and Holscher, A.H. (2001) Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer92: 549-555.
18.
Bonino, J.A. and Sharma, P. (2005) Barrett's esophagus. Curr Opin Gastroenterol21: 461-465.
19.
Bonino, J.A. and Sharma, P. (2006) Barrett's esophagus. Curr Opin Gastroenterol22: 406-411.
20.
Buskens, C.J., van Rees, B.P., Sivula, A., Reitsma, J.B., Haglund, C., Bosma, P.J. et al. (2002) Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology122: 1800-1807.
21.
Buttar, N.S., Wang, K.K., Leontovich, O., Westcott, J.Y., Pacifico, R.J., Anderson, M.A. et al. (2002) Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology122: 1101-1112.
22.
Buttar, N.S., Wang, K.K., Lutzke, L. and Krishnadath, K. (2001a) The use of endoscopic ultrasound in Barrett's esophagus. Gastrointest Endosc53: AB172.
23.
Buttar, N.S., Wang, K.K., Lutzke, L.S., Krishnadath, K.K. and Anderson, M.A. (2001b) Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc54: 682-688.
24.
Buttar, N.S., Wang, K.K., Sebo, T.J., Riehle, D., Krishnadath, K., Lutzke, L. et al. (2001c) Extent of high grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology120: 1630-1639.
25.
Cameron, A.J. (1997) Epidemiology of columnar-lined esophagus and adenocarcinoma . Gastroenterol Clin N Am26: 487-494.
26.
Cameron, A.J., Ott, B.J. and Payne, W.S. (1985) The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med313: 857-858.
27.
Cameron, A.J., Zinsmeister, A.R., Ballard, D.J. and Carney, J.A. (1990) Prevalence of columnar-lined Barrett's esophagus: comparison of population based on clinical and autopsy findings. Gastroenterology99: 918-922.
28.
Castell, D.O. (2001) Medical, surgical, and endoscopic treatment of gastresophageal reflux disease and Barrett's esophagus. J Clin Gastroenterol33: 262-266.
29.
Chak, A., Faulx, A., Kinnard, M., Brock, W., Willis, J., Wiesner, G.L. et al. (2004) Identification of Barrett's esophagus in relatives by endoscopic screening. Am J Gastroenterol99: 2107-2114.
30.
Coad, R.A., Woodman, A.C., Warner, P.J., Barr, H., Wright, N.A. and Shepherd, N.A. (2005) On the histogenesis of Barrett's esophagus and its associated squamous islands: a three-dimensional study of their morphological relationship with native esophageal gland ducts. J Pathol206(4): 388-94.
31.
Conio, M., Blanchi, S., Lapertosa, G., Ferraris, R., Sablich, R., Marchi, S. et al. (2003) Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol98: 1931-1939.
32.
Connor, M., Weston, A.P., Mayo, M.S. and Sharma, P. (2004) The prevalence of Barrett's esophagus and erosive esophagitis in patients undergoing upper endoscopy for dyspepsia in a VA population . Dig Dis Sci49: 920-924.
33.
Corley, D.A., Levin, T.R., Habel, L.A., Weiss, N. and Buffler, P. (2002) Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology122: 633-640.
34.
Csendes, A., Braghetto, I., Burdiles, P., Puente, G., Korn, O., Diaz, J.C. et al. (1998) Long-term results of classic anti-reflux surgery in 152 patients with Barrett's esophagus. Surgery123: 645-657.
35.
Das, A., Wells, C.D., Fleischer, D.E., Kim, H.J. and Sharma, V.K. (2007) Endoscopic ablative therapy is a cost-effective management for non-dysplastic Barrett esophagus. Gastrointest Endosc65: AB151.
36.
DeMeester, S.R. and DeMeester, T.R. (2000) Columnar mucosa and intestinal metaplasia of the esophagus. Fifty years of controversy. Ann Surg231: 303-321.
37.
Devesa, S.S., Blot, W.J. and Fraumeni Jr, J.F. (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer83: 2049-2053.
38.
Dulai, G., Jensen, D.M. and Cortina, G. (2004) MPEC is superior to APC in sustained ablation of Barrett's. Gastroenterology126: A35.
39.
Ell, C., May, A., Gossner, L., Pech, O., Gunter, E., Mayer, G. et al. (2000) Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology118: 670-677.
40.
El-Serag, H.B., Aguirre, T.V., Davis, S., Kuebeler, M., Bhattacharyya, A. and Sampliner, R.E. (2004) Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol99: 1877-1883.
41.
El-Serag, H.B., Kvapil, P., Hacken-Bitar, J. and Kramer, J.R. (2005) Abdominal obesity and the risk of Barrett's esophagus . Am J Gastroenterol100: 2151-2156.
Farrow, D.C. and Vaughan, T.L. (1996) Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control7: 322-327.
44.
Farrow, D.C., Vaughan, T.L., Hansten, P.D., Stanford, J.L., Risch, H.A., Gammon, M.D. et al. (1998) Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer, Cancer Epidemiol Biomarkers Prev3: 97-102.
45.
Fitzgerald, R.C., Omary, M.B. and Triadofilopoulos, G. (1996) Dynamic effects of acid on Barrett's esophagus. J Clin Invest98: 2120-2128.
46.
Fleischer, D., Overholt, B., Sharma, V.K., Reymunde, A., Kimmey, M., Chuttani, R. et al. (2007) Follow-up of AIM-II trial for ablation of Barrett esophagus: results after primary circumferential ablation followed by secondary focal ablation. Gastrointest Endosc65: AB135.
47.
Franchimont, D., Van Laethem, J.-L. and Deviere, J. (2003) Argon plasma coagulation in Barrett's esophagus . Gastrointest Clin Endoscop N Am13: 457-466.
48.
Funkhouser, E.M. and Sharp, G.B. (1995) Aspirin and reduced risk of esophageal carcinoma . Cancer76: 1116-1119.
49.
Ganz, R., Overholt, B., Sharma, V.K., Panjehpour, M., DeMeester, S.R., Bohorfoush, A. et al. (2007) Halo360 circumferential ablation is safe and effective for the treatemtn of Barrett esophagus and high-grade dysplasia: a U.S. multi-center registry. Gastrointest Endosc65: AB147.
50.
Gillen, P., Keeling, P., Byrne, P.J., Healy, M., O'Moore, R.R. and Hennessy, T.P. (1988) Implication of duodenogastric reflux in the pathogenesis of Barrett's esophagus. Br J Surg75: 540-543.
51.
Giovannini, M., Bories, E., Pesenti, C., Moutardier, V., Mongest, G., Danisi, C. et al. (2004) Circumferential endoscopic mucosal resection in Barrett's esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients. Endoscopy36: 782-787.
52.
Gondrie, J.J., Peters, F.P., Curvers, W.L., Sondermeijer, C.M., ten Kate, F., Fockens, P. et al. (2007a) Radiofrequency ablation of Barrett's esophagus containing high-grade dysplasia. Gastrointest Endosc65: AB135.
53.
Gondrie, J.J., Rygiel, A.M., Sondermeijer, C.M., Fockens, P., ten Kate, F., Krishnadath, K.K. et al. (2007b) Balloon-based circumferential ablation followed by focal ablation of Barrett esophagus containing high-grade dysplasia effectively removes all genetic alterations. Gastrointest Endosc132: AB64.
54.
Gossner, L., May, A., Stolte, M., Seitz, G., Hahn, E.G. and Ell, C. (1998a) KTP-laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastrointest Endosc49: 8-12.
55.
Gossner, L., Stolte, M., Sroka, R., Rick, K., May, A., Hahn, E. et al. (1998b) Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid . Gastroenterology114: 448-455.
Headrick, J.R., Nichols, F.C.III, Miller, D.L., Allen, M.S., Trastek, V.F., Deschamps, C. et al. (2002) High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg73: 1697-1702.
58.
Heier, S.K., Rothman, K.A., Heier, L.M. and Rosenthal, W.S. (1995) Photodynamic therapy for obstructing esophageal cancer: light dosimetry and a randomized comparison with Nd : YAG laser therapy . Gastroenterology109: 63-72.
59.
Hesketh, P.J., Clapp, R.W., Doos, W.G. and Spechler, S.J. (1989) The increasing frequency of adenocarcinoma of the esophagus. Cancer64: 526-530.
60.
Hetzel, D.J., Dent, J., Reed, W.D., Nerielvala, F.M., Mackinnon, M., McCarthy, J.H. et al. (1988) Healing and relapse of severe peptic esophagitis after treatement with omeprazole. Gastroenterology95: 903-12.
61.
Holscher, A.H., Bollschweiler, E., Schneider, P.M. and Siewert, J.R. (1997) Early adenocarcinoma in Barrett's esophagus. Br J Surg84: 1470-1473.
62.
Inadomi, J.M., Madanick, R.D., Somsouk, M. and Shaheen, N.J. (2007) Radiofrequency ablation is more cost-effective than endoscopic surveillance or esophagectomy among patients with Barrett's esophagus and low-grade dysplasia. Gastrointest Endosc132: AB53.
63.
Inadomi, J.M., Sampliner, R., Lagergren, J., Lieberman, D., Fendrick, A.M. and Vakil, N. (2003) Screening and surveillance for Barrett's esophagus in high-risk groups: a cost-utility analysis. Ann Int Med138: 176-186.
64.
Irani, S., Parkman, H.P., Thomas, R., Krevsky, B., Fisher, R.S. and Axelrod, P. (2005) Increased Barrett's esophagus for the decade between 1991 and 2000 at a single university medical center. Dig Dis Sci50: 2141-2146.
65.
Johnston, M.H., Eastone, J.A., Horwhat, J.D., Cartledge, J., Mathews, J.S. and Foggy, J.R. (2005) Cryoablation of Barrett's esophagus: a pilot study . Gastrointest Endosc62: 842-848.
66.
Kapoor, N., Ragunath, K., Raman, V.S.V.S., Haqqani, M.T.M.T and Krasner, N. (2002) Endoscopic ablation of dysplastic Barrett's esophagus comparing argon plasma coagulation and photodynamic therapy: long term results of a randomised prospective trial. Gut34(Suppl II): A27.
67.
Katzka, D. and Castell, D.O. (1994) Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in Barrett's esophagus. Am J Gastroentrol89: 989-991.
68.
Kim, R., Weissfeld, J.L., Reynolds, J.C. and Kuller, L.H. (1997) Etiology of Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev6: 369-377.
69.
Kodama, M. and Kakegawa, T. (1998) Treatment of superficial cancer of the esophagus: a summary of responses to a questionnaire on superficial cancer of the esophagus in Japan. Surgery123: 432-439.
70.
Lagergren, J. (2005) Adenocarcinoma of esophagus: what exactly is the size of the problem and who is at risk?Gut54 Suppl 1: 1-5.
71.
Lagergren, J., Bergstrom, R., Lindgren, A. and Nyren, O. (1999) Symptomatic gastro-esophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med340: 825-831.
72.
Larghi, A., Lightdale, C.J., Memeo, L., Bhagat, G., Okpara, N. and Rotterdam, H. (2005) EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc62: 16-23.
73.
Levine, D.S. and Reid, B.J. (1991) Endoscopic technique for acquiring larger mucosal samples. Gastrointest Endosc37: 332-337.
74.
Lightdale, C.J. (1999) Ablation therapy for Barrett's esophagus: is it time to choose our weapons? Gastrointest Endosc49: 122-125.
75.
Lightdale, C.J., Larghi, A., Rotterdam, H. and Okpara, N. (2004) Endoscopic ultrasonography (EUS) and endoscopic mucosal resection (EMR) for staging and treatment of high-grade dysplasia (HGD) and early adenocarcinoma (EAC) in Barrett's esophagus (BE). Gastrointest Endosc59: 90.
76.
Lin, M., Gerson, L.B., Lascar, R., Davila, M. and Triadafilopoulos, G. (2004) Features of gastresophageal reflux disease in women. Am J Gastroenterol99: 1442-1447.
77.
Locke, G.R.III, Talley, N.J., Fett, S.L., Zinsmeister, A.R. and Melton, 3rd L.J. (1997) Prevalence and clinical spectrum of gastresophageal reflux disease: a population based study in Olmsted County, Minnesota. Gastroenterology112: 1448-1456.
78.
Maieron, R., Elli, L., Marino, M., Floriani, I., Minerva, F., Avellini, C. et al. (2005) Celiac disease and intestinal metaplasia of the esophagus (Barrett's esophagus). Dig Dis Sci50: 126-129.
79.
Martin, W.R., Benz, C., Jakobs, R. and Riemann, J.F. (1998) Argon plasma coagulation (APC) in patients with Barrett's esophagus, Gastroenterology114: A60.
80.
Mashimo, H., Wagh, M.S. and Goyal, R.K. (2005) Surveillance and screening for Barrett esophagus and adenocarcinoma. J Clin Gastroenterol39(Suppl. 2): S33-41.
81.
May, A., Gossner, L., Pech, O., Fritz, A., Gunter, E., Mayer, G. et al. (2002) Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's esophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol14: 1085-1091.
82.
Montgomery, E., Bronner, M.P., Goldblum, J.R., Greenson, J.K., Haber, M.M., Hart, J. et al. (2001) Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: a reaffirmation. Hum Pathol32: 368-378.
83.
Montgomery, E., Goldblum, J.R., Greenson, J.K., Haber, M.M., Lamps, L.W., Lauwers, G.Y. et al. (2001) Dysplasia as a predictive marker for invasive cancer in Barrett's esophagus: a follow up study based on 138 cases from a diagnostic variability study. Hum Pathol32: 379-388.
84.
Nebel, O.T., Fornes, M.F. and Castell, D.O. (1976) Symptomatic gastresophageal reflux: incidence and precipitating factors. Am J Dig Dis21: 953-956.
85.
O'Sullivan, G.C., Sheehan, D., Clarke, A., Stuart, R., Kelly, J., Kiely, M.D. et al. (1999) Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology116: 543-548.
86.
Ouatu-Lascar, R., Fitzgerald, R.C. and Triadafilopoulos, G. (1999) Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology117: 327-335.
87.
Overholt, B.F., Panjehpour, M. and Halberg, D.L. (2003) Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc54: 183-188.
88.
Overholt, B.F., Wang, K.K., Burdick, J.S., Lightdale, C.J., Kimmey, M., Nava, H.R. et al. (2007) International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc66: 460-468.
89.
Pasricha, P.J., Hill, S., Wadwa, K.S., Gislason, G.T., Okolo, P.I.III, Magee, C.A. et al. (1998) A second generation endoscopic cryospray: experimental results and first clinical use. Gastrointest Endosc47: 76.
90.
Pech, O., Gossner, L., May, A., Rabenstein, T., Vieth, M., Stolte, M. et al. (2005) Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc62: 24-30.
91.
Peghini, P.L., Katz, P.O., Bracy, N.A. and Castell, D.O. (1989) Nocturnal recovery of gastric acid secretion with twice daily dosing of proton pump inhibitors. Am J Gastroenterol93: 763-767.
92.
Pera, M. (2000) Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent Cancer Res155: 1-14.
93.
Peters, F.T., Ganesh, S., Kuipers, E.J., Sluiter, W.J., Karrenbeld, A., De Jager-Krikken, A. et al. (2000) Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett's esophagus. Scand J Gastroenterol35: 1238-1244.
94.
Peters, F.T., Ganesh, S., Kuipers, E.J., Sluiter, W.J., Klinkenberg-Knol, E.C., Lamers, C.B.H.W. et al. (1999) Endoscopic regression of Barrett's esophagus during omeprazole treatment: a randomised double blind study. Gut45: 489-494.
95.
Peters, F.P., Kara, M.A., Rosmolen, W.D., ten Kate, F.J.W., Bultje, A.C., Krishnadath, K.K. et al. (2005) Endoscopic resection combined with photodynamic therapy for high grade dysplasia and early cancer in Barrett's esophagus. Eur J Gastroenterol Hepatol17: 29-30.
96.
Peters, F.P., Kara, M.A., Rosmolen, W.D., ten Kate, F.J.W., Krishnadath, K.K., van Lanschot, J.J. et al. (2006) Stepwise radial endoscopic resection for complete removal of Barrett's esophagus with early neoplasia: a prospective study. Am J Gastroenterol101: 1449-1457.
97.
Poelmans, J., Feenstra, L., Demedts, I., Rutgeerts, P. and Tack, J. (2004) The yield of upper gastrointestinal endoscopy in patients with suspected reflux-associated chronic ear, nose and throat symptoms' . Am J Gastroenterol99: 1419-1426.
98.
Prasad, G.A., Wang, K.K., Buttar, N.S., Wongkeesong, L.M., Krishnadath, K.K., Nichols, F.C.3rd et al. (2007) Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology132: 1226-1233.
99.
Rastogi, A., Puli, S., El-Serag, H.B., Bansal, A., Wani, S. and Sharma, P. (2008) Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc67: 394-398.
100.
Reid, B.J., Blount, P.L., Feng, Z. and Levine, D.S. (2000a) Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol95: 3089-3096.
101.
Reid, B.J., Haggitt, R.C., Rubin, C.E., Roth, G., Surawicz, C.M., Van Belle, G. et al. (1988) Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol19: 166-178.
102.
Reid, B.J., Levine, D.S., Longton, G., Blount, P.L. and Rabinovitch, P.S. (2000b) Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subjects. Am J Gastroenterol95: 1669-1676.
Ronkainen, J., Aro, P., Storskrubb, T., Johansson, S.E., Lind, T., Bolling-Sternevald, E. et al. (2005) Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology129: 1825-1831.
105.
Rothstein, R., Chang, K., Overholt, B.F., Bergman, J. and Shaheen, N. (2007) Focal ablation for treatment of dysplastic and non-dysplastic Barrett esophagus: safety profile and initial experience with the Halo90 device in 508 cases. Gastrointest Endosc65: AB147.
106.
Sabik, J.F., Rice, T.W., Goldblum, J.R., Koka, A., Kirby, T.J., Medendorp, S.V. et al. (1995) Superficial esophageal adenocarcinoma. Ann Thorac Surg60: 896-902.
107.
Sampliner, R.E. (1997) Ablative therapies for the columnar-lined esophagus . Gastroenterol Clin N Am26: 685-694.
108.
Sampliner, R.E. (2003) Multipolar electrocoagulation. Gastroenterol Clin N Am13: 449-455.
109.
Sampliner, R.E. and the Practice Parameters Committee of the American College of Gastroenterology (2002) Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus . Am J Gastroenterol97: 1888-1895.
110.
Schnell, T., Sontag, S., Chejfec, G., Aranha, G., Metz, A., O'Connell, S. et al. (2001) Long-term non-surgical management of Barrett's esophagus with high grade dysplasia. Gastroenterology120: 1607-1619.
111.
Schulz, H., Miehlke, S., Antos, D., Schentke, K.U., Vieth, M., Stolte, M. et al. (2000) Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high dose omeprazole. Gastrointest Endosc51: 659-663.
112.
Scotiniotis, I.A., Kochman, M.L., Lewis, J.D., Furth, E.E., Rosato, E.F. and Ginsberg, G.G. (2001) Accuracy of EUS in the evaluation of Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc54(6):689-96.
113.
Seewald, S., Akaraviputh, T., Seitz, U., Brand, B., Groth, S., Mendoza, G. et al. (2003) Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma . Gastrointest Endosc57: 854-859.
114.
Shaheen, N.J., Crosby, M.A., Bozymski, E.M. and Sandler, R.S. (2000) Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology119: 333-338.
115.
Shaheen, N.J., Inadomi, J.M., Overholt, B.F. and Sharma, P. (2004) What is the best management strategy for high grade dysplasia in Barrett's esophagus? A cost effectiveness analysis. Gut53: 1736-1744.
116.
Sharma, P., McQuaid, K., Dent, J., Fennerty, M.B., Sampliner, R., Spechler, S. et al. (2004) A critical review of the diagnosis and management of Barrett's esophagus: The AGA Chicago workshop. Gastroenterology127: 310-330.
117.
Sharma, P., Falk, G., Weston, A., Reker, D., Johnston, M. and Sampliner, R. (2006) Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clinical Gastroenterology and Hepatology4(5): 566-72.
118.
Sharma, V.K., Kim, H.J., Musil, D., Crowell, M.D., Dean, P. and Fleischer, D.E. (2007a) Circumferential ablation of Barrett esophagus with low grade dysplasia: one and two year follow up of the AIM-LGD trial . Gastrointest Endosc65: 155.
119.
Sharma, V.K., Wang, K.K., Overholt, B.F., Lightdale, C.J., Fennerty, M.B., Dean, P.J. et al. (2007b) Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow up of 100 patients . Gastrointest Endosc65: 185-195.
120.
Shepherd, N.A. (2000) Dysplasia in Barrett's esophagus. Acta Endoscopica30: 123-132.
121.
Skacel, M., Petras, R.E., Gramlich, T.L., Sigel, J.E., Richter, J.E. and Goldblum, J.R. (2000) The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol95: 3383-3387.
122.
Souza, R.F., Shewmake, K., Beer, D.G., Cryer, B. and Spechler, S.J. (2000) Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res60: 5767-5772.
123.
Souza, R.F., Shewmake, K., Terada, L.S. and Spechler, S.J. (2002) Acid exposure activates the mitogen activated protein kinase pathways in Barrett's esophagus. Gastroenterology122: 299-307.
Spechler, S.J. (2002) Barrett's esophagus. N Engl J Med346: 836-842.
126.
Spechler, S.J. (2003) The natural history of dysplasia and cancer in esophagitis and Barrett esophagus. J Clin Gastroenterol36(5 Suppl): S2-5, S26-8.
127.
Spechler, S.J. and Goyal, R.K. (1985) Barrett's Esophagus: Pathophysiology, Diagnosis and Management. Elsevier: New York .
128.
Spechler, S.J., Lee, E., Ahnen, D., Goyal, R.K., Hirano, I., Ramirez, F. et al. (2001) Long-term outcome of medical and surgical treatments for gastresophageal reflux disease. Follow-up of a randomized controlled trial. JAMA285: 2331-2338.
129.
Spechler, S.J., Jain, S.K., Tendler, D.A. and Parker, R.A. (2002) Racial differences in the frequency of symptoms and complications of gastro-esophageal reflux disease. Aliment Pharmacol Ther16: 1795-1800.
130.
Tan, W.C., Fulljames, C., Stone, N., Dix, A.J., Shepherd, N., Roberts, D.J.H. et al. (1999) Photodynamic therapy using 5-aminolevulinic for esophageal adenocarcinoma associated with Barrett's metaplasia. J Photochem Photobiol B53: 75-80.
131.
Thiesen, J., Nehra, D., Citron, D., Johansson, J., Hagen, J.A., Crookes, P.F. et al. (2000) Suppression of gastric acid secretion in patients with gastresophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg4: 50-54.
132.
Thomas, P., Doddoli, C., Lienne, P., Morati, N., Thirion, X., Garbe, L. et al. (1997) Changing patterns and surgical results in adenocarcinoma of the esophagus. Br J Surg84: 119-125.
133.
Toruner, M., Soykan, I., Ensari, A., Kuzu, I., Yurdaydin, C. and Ozden, A. (2004) Barrett's esophagus: prevalence and its relationship with dyspeptic symptoms. J Gastroenterol Hepatol19: 535-540.
134.
Trier, J.S. (1970) Morphology of the epithelium of the distal esophagus in patients with mild esophageal strictures. Gastroenterology58: 444-461.
135.
Tsibouris, P., Hendrickse, T. and Isaacs, P. (2004) Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's esophagus who develop an esophageal adenocarcinoma. Aliment Pharmacol Ther20: 645-655.
136.
Van Blankenstein, M., Bohmer, C.J.M. and Hop, W.C.J. (2004) The incidence of adenocarinoma in Barrett's esophagus in an institutionalized population. Eur J Gastroenterol Hepatol16: 903-909.
137.
Van Blankenstein, M., Looman, C.W.N., Johnston, B.J. and Caygill, C.P.J. (2005) Age and sex distribution of the prevalence of Barrett's esophagus found in a primary referral endoscopy center. Am J Gastroenterol100: 568-576.
138.
Van der Veen, A.H., Dees, J., Blankensteijn, J.D. and Van Blankenstein, M. (1989) Adenocarcinoma in Barrett's esophagus: an overrated risk. Gut30: 14-18.
139.
Van Sandick, J.W., Van Lanschot, J.J., Kuiken, B.W., Tytgat, G.N.J., Offerhaus, G.J. and Obertop, H. (1998) Impact of endoscopic biopsy surveillance of Barrett's esophagus on pathological stage and clinical outcome of Barrett's carcinoma . Gut43: 216-222.
140.
Verdu, E., Viani, F., Armstrong, D., Fraser, R., Siegrist, H.H., Pignatelli, B. et al. (1994) Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut35: 455-460.
141.
Wang, K.K. and Sampliner, R.B. (2008) Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus. Am J Gastroenterol103: 788.
142.
Westhoff, B., Brotze, S., Weston, A., McElhinney, C., Cherian, R., Mayo, M. et al. (2005) The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc61: 226-231.
143.
Weston, A.P., Banerjee, S.K., Sharma, P., Tran, T.M., Richards, R. and Cherian, R. (2001) p53 overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression . Am J Gastroenterol96: 1355-1362.
144.
Weston, A.P., Sharma, P., Topalovski, M., Richards, R., Cherian, R. and Dixon, A. (2000) Long-term follow up of Barrett's high-grade dysplasia . Am J Gastroenterol95: 1888-1893.
145.
Wilson, K.T., Fu, S., Ramanujam, K.S. and Meltzer, S.K. (1998) Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas . Cancer Res58: 2929-2934.
146.
Wipff, J., Allanore, Y., Soussi, F., Terris, B., Abitbol, V., Raymond, J. et al. (2005) Prevalence of Barrett's esophagus systematic sclerosis. Arthritis Rheum52: 2882-2888.
147.
Yang, P.C. and Davis, S. (1988) Incidence of cancer of the esophagus in the US by histologic type. Cancer61: 612-617.
148.
Ye, W., Chow, W., Lagergren, J., Lin, O. and Nyren, O. (2001) Risk of adenocarcinoma of the esophagus and gastric cardia in patients with gastresophageal reflux diseases and after reflux surgery . Gastroenterology121: 1286-1293.
